Molecular Cancer (Jul 2022)
CDC6 is a prognostic biomarker and correlated with immune infiltrates in glioma
- Feng Wang,
- Fen Zhao,
- Li Zhang,
- Lai Xiong,
- Qing Mao,
- Yanhui Liu,
- Xiaoguang Qiu,
- Xiang Wang,
- Lin Shui,
- Xi Chen,
- Kexing Ren,
- Pixian Shui,
- Qiongwen Zhang,
- Yifei Deng,
- Weimin Li,
- Xiaoqi Xie,
- Dengbin Wu,
- Tao Li,
- Jinyi Lang,
- Lei Liu,
- Huaying Chen,
- Jianguo Xu,
- Sen Bai,
- Zhiping Li,
- Qiang Yue,
- Ni Chen,
- Bingwen Zhou,
- Cheng Yi,
- Yuquan Wei,
- Yuchuan Fu,
- Yong Luo,
- Qiheng Gou,
- Lunxu Liu,
- Yuanzhao Liu,
- Jingbo Kang,
- Junjie Wang,
- Dongcun Jing,
- Fuquan Zhang,
- Xiaoyan Yang,
- Xianfeng Li,
- Tao Jiang,
- Zongcun Zhang,
- Yizhi Zhou,
- Junlin Yi
Affiliations
- Feng Wang
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Fen Zhao
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Li Zhang
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Lai Xiong
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Qing Mao
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Yanhui Liu
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Xiaoguang Qiu
- Department of Radiotherapy, Beijing Tian Tan Hospital, Capital Medical University
- Xiang Wang
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Lin Shui
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Xi Chen
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Kexing Ren
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Pixian Shui
- Department of Pharmacy, Affiliated Hospital of Southwest Medical University
- Qiongwen Zhang
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Yifei Deng
- Department of Radiotherapy, Chengdu Seventh Hospital
- Weimin Li
- Center for Precision Medicine, West China Hospital, Sichuan University
- Xiaoqi Xie
- Department of Critical Care Medicine, West China Hospital, Sichuan University
- Dengbin Wu
- Cancer Hospital, An Steel Group General Hospital
- Tao Li
- Department of Radiotherapy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China
- Jinyi Lang
- Department of Radiotherapy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China
- Lei Liu
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Huaying Chen
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Jianguo Xu
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Sen Bai
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Zhiping Li
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Qiang Yue
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Ni Chen
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Bingwen Zhou
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Cheng Yi
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Yuquan Wei
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Yuchuan Fu
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Yong Luo
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Qiheng Gou
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Lunxu Liu
- Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University
- Yuanzhao Liu
- Department of Radiotherapy, Beijing Hospital
- Jingbo Kang
- Department of Radiotherapy, The sixth Medical Center of PLA General Hospital
- Junjie Wang
- Department of Radiation Oncology, Peking University Third Hospital
- Dongcun Jing
- Kawagawa Hospital Tsukiji
- Fuquan Zhang
- Department of Radiation Oncology, Beijing Union Medical College Hospital
- Xiaoyan Yang
- Department of Radiotherapy, First Hospital of Shan Xi Medical, University, Taiyuan West
- Xianfeng Li
- Department of Radiotherapy, First Hospital of Shan Xi Medical, University, Taiyuan West
- Tao Jiang
- Department of Radiotherapy, Beijing Tian Tan Hospital, Capital Medical University
- Zongcun Zhang
- Qing Dao Central Hospital
- Yizhi Zhou
- Shanghai High-Tech United Bio-Technological R&D Co., Ltd
- Junlin Yi
- Department of Radiation Oncology, National Cancer Center National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- DOI
- https://doi.org/10.1186/s12943-022-01623-8
- Journal volume & issue
-
Vol. 21,
no. 1
pp. 1 – 9
Abstract
Abstract Background Cell division cycle 6 (CDC6) has been proven to be associated with the initiation and progression of human multiple tumors. However, it’s role in glioma, which is ranked as one of the common primary malignant tumor in the central nervous system and is associated with high morbidity and mortality, is unclear. Methods In this study, we explored CDC6 gene expression level in pan-cancer. Furthermore, we focused on the relationships between CDC6 expression, its prognostic value, potential biological functions, and immune infiltrates in glioma patients. We also performed vitro experiments to assess the effect of CDC6 expression on proliferative, apoptotic, migrant and invasive abilities of glioma cells. Results As a result, CDC6 expression was upregulated in multiple types of cancer, including glioma. Moreover, high expression of CDC6 was significantly associated with age, IDH status, 1p/19q codeletion status, WHO grade and histological type in glioma (all p < 0.05). Meanwhile, high CDC6 expression was associated with poor overall survival (OS) in glioma patients, especially in different clinical subgroups. Furthermore, a univariate Cox analysis showed that high CDC6 expression was correlated with poor OS in glioma patients. Functional enrichment analysis indicated that CDC6 was mainly involved in pathways related to DNA transcription and cytokine activity, and Gene Set Enrichment Analysis (GSEA) revealed that MAPK pathway, P53 pathway and NF-κB pathway in cancer were differentially enriched in glioma patients with high CDC6 expression. Single-sample gene set enrichment analysis (ssGSEA) showed CDC6 expression in glioma was positively correlated with Th2 cells, Macrophages and Eosinophils, and negative correlations with plasmacytoid dendritic cells, CD8 T cells and NK CD56bright cells, suggesting its role in regulating tumor immunity. Finally, CCK8 assay, flow cytometry and transwell assays showed that silencing CDC6 could significantly inhibit proliferation, migration, invasion, and promoted apoptosis of U87 cells and U251 cells (p < 0.05). Conclusion In conclusion, high CDC6 expression may serve as a promising biomarker for prognosis and correlated with immune infiltrates, presenting to be a potential immune therapy target in glioma.
Keywords
